Takinib
Takinib Basic information
- Product Name:
- Takinib
- Synonyms:
-
- Takinib
- 1-N-(1-propyl-1H-1,3-benzodiazol-2-yl)benzene-1,3-dicarboxamide
- N-(1-Propyl-1H-benzo[d]imidazol-2-yl)isophthalamide
- 3-N-(1-propylbenzimidazol-2-yl)benzene-1,3-dicarboxamide
- N1-(1-Propyl-1H-benzo[d]imidazol-2-yl)isophthalamide
- EDHS-206
- 1,3-Benzenedicarboxamide, N1-(1-propyl-1H-benzimidazol-2-yl)-
- Takinib >=98% (HPLC)
- CAS:
- 1111556-37-6
- MF:
- C18H18N4O2
- MW:
- 322.36
- Mol File:
- 1111556-37-6.mol
Takinib Chemical Properties
- Density
- 1.30±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- DMSO:30.0(Max Conc. mg/mL);93.06(Max Conc. mM)
- form
- A solid
- pka
- 12.13±0.43(Predicted)
- color
- White to off-white
- SMILES
- CCCN1C2=CC=CC=C2N/C1=N\C(C3=CC(C(N)=O)=CC=C3)=O
Takinib Usage And Synthesis
Uses
Takinib has been used as an inhibitor of transforming 28 growth factor - β-activated kinase -1 (TAK-1) in human leukemia monocytic THP-1 cells. It may be used as a TAK1 inhibitor in Jurk at cells.
Biological Activity
Takinib is a selective inhibitor of TAK1/MAP3K7 kinase, which is a member of the MAP3K family and a key regulator of cell death. It binds in the TAk1 ATPbinding pocket with an IC50 value of 9.5 nM. Takinib selectively induced apoptosis following TNF-α stimulation in rheumatoid arthritis and breast cancer.
in vivo
Takinib (50 mg/kg; intraperitoneally; daily from days 18-36) reduces the clinical score in type II collagen-induced arthritis (CIA) mouse model of rheumatoid arthritis[4].
Takinib (50 mg/kg; oral gavage; daily until 17 days) slows tumor growth in the Hodgkin lymphoma xenograft NSG mice[5].
| Animal Model: | Male DBA/1 mice (CIA arthritis model)[4] |
| Dosage: | 50 mg/kg |
| Administration: | Intraperitoneally; daily from days 18-36 |
| Result: | Showed a reduction in clinical arthritic score compared to vehicle control. |
| Animal Model: | Female NSG mice (8 weeks old)[5] |
| Dosage: | 50 mg/kg |
| Administration: | Oral gavage; daily until 17 days |
| Result: | Slowed tumor growth and reduced tumor size/weight. |
IC 50
TAK1: 9.5 nM (IC50); IRAK4: 120 nM (IC50); IRAK1: 390 nM (IC50); GCK: 430 nM (IC50); CLK2: 430 nM (IC50); MINK1: 1.9 μM (IC50)
storage
Store at -20°C
Background
Takinib is a potent and selective small molecule inhibitor of TAK1, a MAP3K family protein and important moderator of cell survival and death in TNF-α signaling. Takinib preferentially binds and inhibits TAK1 over other targets. The inhibitor Takinib induces apoptosis following TNF-α stimulation in cell models of rheumatoid arthritis and metastatic breast cancer. Inhibition of TAK1 by Takinib resulted in increased cell death in several cancer cell lines, and reduced pro-inflammatory and pro-angiogenic signaling in tumor-associated macrophages, suggesting that Takinib regulation of TAK1 may be a beneficial therapeutic strategy. Additional evidence suggests that Takinib inhibition of cytokine production may also work along additional pathways, including the JAK/STAT pathway. In a study examining inflammation in human rheumatoid arthritis synovial fibroblasts, treatment with Takinib results in specifically reduced IL-1β-induced STAT3 phosphorylation, nuclear translocation, and DNA binding.
References
[1] Totzke, J. et al. (2017) Cell Chem Biol 24, 1029-1039.e7.
[2] Scarneo, S.A. et al. (2020) Oncotarget 11, 1961-1970.
[3] Panipinto, P.M. et al. (2021) Int J Mol Sci 22, 12580. doi: 10.3390/ijms222212580.
TakinibSupplier
- Tel
- 025-84699383-8003;025-846993838003-8003 18013301593;18013301590
- njduly@126.com
- Tel
- 400-400-164-7117 18317119277
- product02@bidepharm.com
- Tel
- 025-58849295 18951903616;
- info@adooq.cn
- Tel
- 13621943973
- sales@shjiyipharmatech.com
- Tel
- 021-52996696,15000506266 15000506266